Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Platinum

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Platinum

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 25,042Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tubulis Receives FDA Fast Track for TUB-040 in Ovarian Cancer
    Tubulis Receives FDA Fast Track for TUB-040 in Ovarian Cancer

    27 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240627580631/en

    BUSINESSWIRE
    27 Jun 2024
    Share Share
    Aravive Receives Third Development Milestone from 3D Medicines
    Aravive Receives Third Development Milestone from 3D Medicines

    10 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/10/2531336/30446/en/Aravive-Receives-Third-Development-Milestone-from-3D-Medicines.html

    GLOBENEWSWIRE
    10 Oct 2022
    Share Share
    Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination
    Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination

    20 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/20/2519421/0/en/Junshi-Biosciences-Receives-NMPA-Approval-of-sNDA-for-Toripalimab-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Advanced-Non-squamous-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    20 Sep 2022
    Share Share
    Motto International Corp. Issues Voluntary Recall of Bull Platinum
    Motto International Corp. Issues Voluntary Recall of Bull Platinum

    19 Dec 2019

    // FDA

    https://www.pharmacompass.com/pdf/news/motto-international-corp-issues-voluntary-recall-of-bull-platinum-1576839037.pdf

    FDA
    19 Dec 2019
    Share Share
    Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA®
    Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA®

    19 Oct 2019

    // BIOSPACE

    https://www.biospace.com/article/releases/merck-receives-positive-eu-chmp-opinion-for-two-new-regimens-of-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma-/?s=95

    BIOSPACE
    19 Oct 2019
    Share Share
    AstraZeneca’s Imfinzi tees up lung cancer fight with Roche
    AstraZeneca’s Imfinzi tees up lung cancer fight with Roche

    28 Jun 2019

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/marketing/astrazeneca-s-imfinzi-hits-survival-goal-tees-up-small-cell-lung-cancer-i-o-fight-roche

    Angus Liu FIERCE PHARMA
    28 Jun 2019
    Share Share